Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review

por Nagaraj, Gayathri, Ma, Cynthia X.
Publicado 2020

Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer

por Ademuyiwa, Foluso O., Ellis, Matthew J., Ma, Cynthia X.
Publicado 2013

PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer

por Rajput, Sandeep, Guo, Zhanfang, Li, Shunqiang, Ma, Cynthia X.
Publicado 2019

KSTAR: An algorithm to predict patient-specific kinase activities from phosphoproteomic data

por Crowl, Sam, Jordan, Ben T., Ahmed, Hamza, Ma, Cynthia X., Naegle, Kristen M.
Publicado 2022

Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer

por Rajput, Sandeep, Khera, Nimmish, Guo, Zhanfang, Hoog, Jeremy, Li, Shunqiang, Ma, Cynthia X.
Publicado 2016

Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy

por Dehdashti, Farrokh, Wu, Ningying, Ma, Cynthia X., Naughton, Michael J., Katzenellenbogen, John A., Siegel, Barry A.
Publicado 2021

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

por Sanchez, Cesar G, Ma, Cynthia X, Crowder, Robert J, Guintoli, Therese, Phommaly, Chanpheng, Gao, Feng, Lin, Li, Ellis, Matthew J
Publicado 2011

Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer

por Kalra, Maitri, Tong, Yan, Jones, David R., Walsh, Tom, Danso, Michael A., Ma, Cynthia X., Silverman, Paula, King, Mary-Claire, Badve, Sunil S., Perkins, Susan M., Miller, Kathy D.
Publicado 2021

Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent

por Marquez-Nostra, Bernadette V., Lee, Supum, Laforest, Richard, Vitale, Laura, Nie, Xingyu, Hyrc, Krzysztof, Keler, Tibor, Hawthorne, Thomas, Hoog, Jeremy, Li, Shunqiang, Dehdashti, Farrokh, Ma, Cynthia X., Lapi, Suzanne E.
Publicado 2017

RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies

por van de Stolpe, Anja, Verhaegh, Wim, Blay, Jean-Yves, Ma, Cynthia X., Pauwels, Patrick, Pegram, Mark, Prenen, Hans, De Ruysscher, Dirk, Saba, Nabil F., Slovin, Susan F., Willard-Gallo, Karen, Husain, Hatim
Publicado 2021

Cancer-associated exportin-6 upregulation inhibits the transcriptionally repressive and anticancer effects of nuclear profilin-1

por Zhu, Cuige, Kim, Sun-Joong, Mooradian, Arshag, Wang, Faliang, Li, Ziqian, Holohan, Sean, Collins, Patrick L., Wang, Keren, Guo, Zhanfang, Hoog, Jeremy, Ma, Cynthia X., Oltz, Eugene M., Held, Jason M., Shao, Jieya
Publicado 2021

Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models

por Guo, Zhanfang, Primeau, Tina, Luo, Jingqin, Zhang, Cynthia, Sun, Hua, Hoog, Jeremy, Gao, Feng, Huang, Shixia, Edwards, Dean P., Davies, Sherri R., Aft, Rebecca, Ding, Li, Ellis, Matthew J., Li, Shunqiang, Ma, Cynthia X.
Publicado 2020

Aromatase Gene Polymorphisms Are Associated with Survival among Patients with Cardiovascular Disease in a Sex-Specific Manner

por Beitelshees, Amber L., Johnson, Julie A., Hames, Megan L., Gong, Yan, Cooper-DeHoff, Rhonda M., Wu, Jun, Cresci, Sharon, Ma, Cynthia X., Pepine, Carl J., Province, Michael A., Spertus, John A., McLeod, Howard L.
Publicado 2010

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

por Bagegni, Nusayba, Thomas, Shana, Liu, Ning, Luo, Jingqin, Hoog, Jeremy, Northfelt, Donald W., Goetz, Matthew P., Forero, Andres, Bergqvist, Mattias, Karen, Jakob, Neumüller, Magnus, Suh, Edward M., Guo, Zhanfang, Vij, Kiran, Sanati, Souzan, Ellis, Matthew, Ma, Cynthia X.
Publicado 2017

A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis

por Krishnamurthy, Jairam, Luo, Jingqin, Suresh, Rama, Ademuyiwa, Foluso, Rigden, Caron, Rearden, Timothy, Clifton, Katherine, Weilbaecher, Katherine, Frith, Ashley, Roshal, Anna, Tandra, Pavan K., Cherian, Mathew, Summa, Tracy, Haas, Brittney, Thomas, Shana, Hernandez-Aya, Leonel, Bergqvist, Mattias, Peterson, Lindsey, Ma, Cynthia X.
Publicado 2022

Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor...

por Gerratana, Lorenzo, Davis, Andrew A., Velimirovic, Marko, Clifton, Katherine, Hensing, Whitney L., Shah, Ami N., Dai, Charles S., Reduzzi, Carolina, D’Amico, Paolo, Wehbe, Firas, Medford, Arielle, Wander, Seth A., Gradishar, William J., Behdad, Amir, Puglisi, Fabio, Ma, Cynthia X., Bardia, Aditya, Cristofanilli, Massimo
Publicado 2023

Proteins in Tumor-Derived Plasma Extracellular Vesicles Indicate Tumor Origin

por Barlin, Meltem, Erdmann-Gilmore, Petra, Mudd, Jacqueline L., Zhang, Qiang, Seymour, Robert W., Guo, Zhanfang, Miessner, Julia R., Goedegebuure, S. Peter, Bi, Ye, Osorio, Omar A., Alexander-Brett, Jennifer, Li, Shunqiang, Ma, Cynthia X., Fields, Ryan C., Townsend, R. Reid, Held, Jason M.
Publicado 2022

Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic

por Dowsett, Mitch, Ellis, Matthew J., Dixon, J. Michael, Gluz, Oleg, Robertson, John, Kates, Ronald, Suman, Vera J., Turnbull, Arran K., Nitz, Ulrike, Christgen, Matthias, Kreipe, Hans, Kuemmel, Sherko, Bliss, Judith M., Barry, Peter, Johnston, Stephen R., Jacobs, Samuel A., Ma, Cynthia X., Smith, Ian E., Harbeck, Nadia
Publicado 2020

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast canc...

por Bardia, Aditya, Mayer, Ingrid, Winer, Eric, Linden, Hannah M., Ma, Cynthia X., Parker, Barbara A., Bellet, Meritxell, Arteaga, Carlos L., Cheeti, Sravanthi, Gates, Mary, Chang, Ching-Wei, Fredrickson, Jill, Spoerke, Jill M., Moore, Heather M., Giltnane, Jennifer, Friedman, Lori S., Chow Maneval, Edna, Chan, Iris, Jhaveri, Komal
Publicado 2022

A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)

por Ademuyiwa, Foluso O., Northfelt, Donald W., O’Connor, Tracey, Levine, Ellis, Luo, Jingqin, Tao, Yu, Hoog, Jeremy, Laury, Marie L., Summa, Tracy, Hammerschmidt, Trish, Guo, Zhanfang, Frith, Ashley, Weilbaecher, Katherine, Opyrchal, Mateusz, Aft, Rebecca, Clifton, Katherine, Suresh, Rama, Bagegni, Nusayba, Hagemann, Ian S., Iglesia, Michael D., Ma, Cynthia X.
Publicado 2023